UCLA Heart Failure Symposium 2019

Researchers have mapped the active-state structure of the angiotensin II type 1 receptor, the target of widely prescribed drugs to regulate blood pressure and kidney function. The study, published online Jan. 10 in Cell, was conducted by researchers in the Blavatnik Institute at Harvard Medical School and colleagues at Duke University Medical Center.


The higher expense and lower frame rates of 3-D cardiac ultrasound systems have limited their adoption over the past decade and have begged the question at the annual American Society of Echocardiography (ASE) meetings whether 3-D is a necessary technology. However, sessions at ASE 2018 showed the focus on 3-D imaging systems has definitely changed from a research tool to a front-line echo workhorse.


January 31, 2019 — Nearly half (48 percent, 121.5 million in 2016) of all adults in the United States have some type of cardiovascular disease, according to new statistics released by the American Heart Association (AHA). The AHA Heart and Stroke Statistics — 2019 Update are published in the association’s journal Circulation.1

Northwestern Medicine scientists have discovered a novel signaling pathway that promotes healing after a heart attack. The study, published in Cell Metabolism, demonstrates for the first time that the metabolism of dead heart cells by macrophages reprograms the immune cells to launch an anti-inflammatory response and stimulate tissue repair.

Rising temperatures stemming from global climate change may increase the number of infants born with congenital heart defects (CHD) in the U.S. over the next two decades, according to new research in the Journal of the American Heart Association.1 This may also result in as many as 7,000 additional cases over an 11 year-period in eight representative states — Arkansas, Texas, California, Iowa, North Carolina, Georgia, New York and Utah.


January 30, 2019 — Updated atrial fibrillation (AFib) treatment guidelines released this week now recommend new oral anticoagulants (NOACs) as the preferred alternative to warfarin for reducing the risk of stroke.


In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat peripheral artery disease (PAD). Part of this has been fueled by the rising numbers of peripheral interventional procedures for PAD, critical limb ischemia (CLI, also called chronic limb-threatening ischemia) and limb salvage to prevent amputation. But new technology development also has been spurred by the need to reduce extremely high restenosis rates.


The U.S. Food and Drug Administration (FDA) has cleared the Magnetom Lumina 3 Tesla (3T) magnetic resonance imaging (MRI) scanner from Siemens Healthineers.

Subscribe Now